At present, the definitive diagnosis of Alzheimer's disease (AD) is based on the pathologic confirmation of amyloid plaques and neurofibrillary tangles in the cerebral cortex. Over many years, our research efforts have been directed toward the development of non-invasive methods for the in vivo measurement of amyloid plaques. Toward this goal, our group recently collaborated with researchers in Uppsala, Sweden, to perform the first human positron emission tomography (PET) studies of a new amyloidbinding radiotracer, named PIB (Pittsburgh Compound B). These first human studies demonstrated high PIB retention in AD subjects (n=9) in brain areas known to have high amyloid levels in AD (relative to controls, n=5). The next step in our efforts is to establish the validity of the PIB PET methodology and to determine a valid and simple method for potential clinical use. The central goal of this application is to validate the PIB PET methodology and identify a simple PIB measure of amyloid-binding that is feasible for routine use. Toward this goal, PIB PET studies will be acquired in 3 subject groups: mild-to-moderate AD dementia (n=12), mild cognitive impairment (n=12), and elderly controls (n=12). PIB localization will be related to measures of brain glucose metabolism (using [18F]FDG), which has been extensively used as a metabolic index of AD. Validation will include acquisition of [15O]water PET data to exclude the influence of variations in blood flow on PIB binding. Structural MRI data will be acquired in all subjects to provide anatomical guidance for the PET data analyses.
Our first aim i s to identify an optimal fully-quantitative (arterial blood) PIB PET method.
The second aim i s to choose a valid and simple (no blood sampling) PIB PET method based upon the fully-quantitative data and an iterative evaluation of observed and computer-simulated PIB data. The simple method will allow rapid generation of robust image maps of amyloid binding throughout brain.
The final aim i s to relate anatomically standardized maps of amyloid binding to maps of cerebral metabolism. This research will provide important groundwork to support the use of the PIB measure of amyloid binding in early and pre-clinical diagnosis of AD and potentially accelerate the development and evaluation of important new therapies for dementia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH070729-01
Application #
6767220
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Brady, Linda S
Project Start
2004-05-13
Project End
2007-04-30
Budget Start
2004-05-13
Budget End
2005-04-30
Support Year
1
Fiscal Year
2004
Total Cost
$390,752
Indirect Cost
Name
University of Pittsburgh
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Yin J; Rosario, Bedda L; Mowrey, Wenzhu et al. (2015) Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET. J Nucl Med 56:1199-205
Mathis, Chester A; Kuller, Lewis H; Klunk, William E et al. (2013) In vivo assessment of amyloid-? deposition in nondemented very elderly subjects. Ann Neurol 73:751-61
D'Angelo, Gina M; Weissfeld, Lisa A (2013) Application of copulas to improve covariance estimation for partial least squares. Stat Med 32:685-96
Price, Julie C (2012) Molecular brain imaging in the multimodality era. J Cereb Blood Flow Metab 32:1377-92
Mathis, Chester A; Mason, N Scott; Lopresti, Brian J et al. (2012) Development of positron emission tomography ?-amyloid plaque imaging agents. Semin Nucl Med 42:423-32
Rosario, Bedda L; Weissfeld, Lisa A; Laymon, Charles M et al. (2011) Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. Neuroimage 55:933-41
Jagust, W J; Landau, S M; Shaw, L M et al. (2009) Relationships between biomarkers in aging and dementia. Neurology 73:1193-9
Wolk, David A; Price, Julie C; Saxton, Judy A et al. (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65:557-68
Cohen, Ann D; Price, Julie C; Weissfeld, Lisa A et al. (2009) Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 29:14770-8
Reiman, Eric M; Chen, Kewei; Liu, Xiaofen et al. (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106:6820-5

Showing the most recent 10 out of 25 publications